Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy
Science Advances · 14.03.2025 · 11 (11)
DOI: 10.1126/sciadv.adr4443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 14.03.2025. Verfasst von Eun Young Jeon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Enhancer of Zeste Homolog 2 Protein, Glucocorticoids, Steroids. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is a devastating X-linked disorder caused by dystrophin gene mutations. Despite recent advances in understanding the disease etiology and applying emerging treatment methodologies, glucocorticoid derivatives remain the only general therapeutic option that can slow disease development. However, the precise molecular mechanism of glucocorticoid action remains unclear, and there is still need for additional remedies to complement the treatment. Here, using single-nucleus RNA sequencing and spatial transcriptome analyses of human and mouse muscles, we investigated pathogenic features in patients with DMD and palliative effects of glucocorticoids. Our approach further illuminated the importance of proliferating satellite cells and revealed increased activity of a signal transduction pathway involving EZH2 in the patient cells. Subsequent administration of EZH2 inhibitors to Dmd mutant mice resulted in improved muscle phenotype through maintaining the immune-suppressing effect but overriding the muscle weakness and fibrogenic effects exerted by glucocorticoids. Our analysis reveals pathogenic mechanisms that can be readily targeted by extant therapeutic options for DMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Information Convergence Engineering, Pusan National University, Yangsan, Republic of Korea.
- Department of Pharmacology, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
- Department of Genomic Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Pediatrics, Rare Disease Center, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Eun Young Jeon, Yejin Kwak, Hyeji Kang, Hanbyeol Kim, Se Young Jin, Soojin Park, Ryeo Gyeong Kim, Dayoung Ko, Jae-Kyung Won, Anna Cho, Inkyung Jung, Chul-Hwan Lee, Jeongbin Park, Hyun-Young Kim, Jong-Hee Chae, Murim Choi
Zitieren
APA
Jeon, E. Y., Kwak, Y., Kang, H., Kim, H., Jin, S. Y., Park, S., Kim, R. G., Ko, D., Won, J. K., Cho, A., Jung, I., Lee, C. H., Park, J., Kim, H. Y., Chae, J. H., & Choi, M. (2025). Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy. Science Advances, 11(11). https://doi.org/10.1126/sciadv.adr4443
Vancouver
Jeon EY, Kwak Y, Kang H, Kim H, Jin SY, Park S, et al. Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy. Science Advances. 2025;11(11). doi:10.1126/sciadv.adr4443
BibTeX
@article{Jeon2025,
author = {Jeon, Eun Young and Kwak, Yejin and Kang, Hyeji and Kim, Hanbyeol and Jin, Se Young and Park, Soojin and Kim, Ryeo Gyeong and Ko, Dayoung and Won, Jae-Kyung and Cho, Anna and Jung, Inkyung and Lee, Chul-Hwan and Park, Jeongbin and Kim, Hyun-Young and Chae, Jong-Hee and Choi, Murim},
title = {Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {11},
doi = {10.1126/sciadv.adr4443}
}
EUVIMED